Novo Nordisk (Ozempic)
Acquired
The Journey of GLP-1: From Skepticism to Success
This chapter explores the challenging path of developing GLP-1 therapeutics for type 2 diabetes, focusing on liraglutide's innovative modifications for enhanced stability and efficacy. It highlights the determination of researchers amid skepticism and management pressures, revealing the complexity of drug development from lab to market. The narrative also uncovers the surprising origins of GLP-1 analogs, including connections to lizard venom, and examines the societal implications of weight management therapies.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
